Efficacy of neo- and adjuvant treatment modalities in gastrointestinal cancer patients.
Data which have emerged from randomized clinical trials are inconclusive regarding the efficacy of neoadjuvant chemoradiation therapy for patients with esophageal cancer. In 2001, available data appear to support the use of adjuvant chemoradiation therapy following the complete resection of a gastric cancer, adjuvant chemotherapy following the resection of a stage III (and--probably--"high-risk" stage II) colon cancer, and the use of adjuvant (and most likely neoadjuvant) chemoradiation therapy for stages II and III rectal cancer.
Mayer
R J
RJ
Center for Gastrointestinal Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D005770:Gastrointestinal Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D006801:Humans; D020360:Neoadjuvant Therapy; D009367:Neoplasm Staging; D018714:Radiotherapy, Adjuvant; D015996:Survival Rate